NCT06785974View on ClinicalTrials.gov

Statins to Prevent Immune Checkpoint Inhibitor-induced PRogression of AtherosLerosis

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

February 28, 2025

Primary Completion Date

February 28, 2027

Study Completion Date

February 28, 2030

Conditions
AtherosclerosisMelanomaImmune-related Adverse Event
Interventions
DRUG

Atorvastatin

Daily 20mg atorvastatin.

DRUG

Placebo

Daily Placebo in combination with ICI-therapy

Trial Locations (1)

3015GD

Erasmus Universitair Medisch Cetrum Rotterdam, Rotterdam

Sponsors
All Listed Sponsors
collaborator

Amphia Hospital

OTHER

lead

Erasmus Medical Center

OTHER